L A Reiter

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Difluoroketones as inhibitors of matrix metalloprotease-13
    L A Reiter
    Pfizer Inc, Central Research Division, Groton, CT 06340, USA
    Bioorg Med Chem Lett 10:1581-4. 2000
  2. ncbi request reprint Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3
    Lawrence A Reiter
    Pfizer Inc, Global Reseach and Development, Groton Laboratories, Eastern Point Rd, 06340, Groton, CT, USA
    Bioorg Med Chem Lett 13:2331-6. 2003
  3. ncbi request reprint Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1
    Lawrence A Reiter
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 14:3389-95. 2004
  4. ncbi request reprint Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14
    Julian A Blagg
    Pfizer Global Research and Development, Groton Laboratories, MS8220 2471, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 15:1807-10. 2005
  5. ncbi request reprint Potent, selective pyrimidinetrione-based inhibitors of MMP-13
    Lawrence A Reiter
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 16:5822-6. 2006
  6. ncbi request reprint Pyrimidine benzamide-based thrombopoietin receptor agonists
    Lawrence A Reiter
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 17:5447-54. 2007
  7. ncbi request reprint A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif
    Amit S Kalgutkar
    Pharmacokinetics, Dynamics and Metabolism Department, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Chem Res Toxicol 20:1954-65. 2007
  8. ncbi request reprint Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13
    Kevin D Freeman-Cook
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 17:6529-34. 2007
  9. doi request reprint Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonists
    Lawrence A Reiter
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 18:3000-6. 2008

Collaborators

  • Ellen R Laird
  • Christopher L Shaffer
  • Amit S Kalgutkar
  • Gregory S Walker
  • Mark C Noe
  • Kim F McClure
  • Sabrina X Zhao
  • Kevin D Freeman Cook
  • Kevin D Freeman-Cook
  • Marcie L Vaughn-Bowser
  • Peter G Mitchell
  • James T Downs
  • Jennifer L Liras
  • Joel R Hardink
  • James D Eskra
  • Jayvardhan Pandit
  • Christopher S Jones
  • Richard J Griffiths
  • Sue A Yocum
  • Lori L Lopresti-Morrow
  • Dennis E Danley
  • Julian A Blagg
  • Shane Eisenbeis
  • Amy S Antipas
  • Kaushik Datta
  • Fouad Janat
  • Usa D Reilly
  • Lilli A Wolf-Gouviea
  • David J Garmene
  • Donald Robertson
  • Gary J Martinelli
  • Elaine M Greer
  • Roberto Guzman
  • Ralph P Robinson
  • Lilli A Wolf-Gouveia
  • Chakrapani Subramanyam
  • Nancy C Elliott
  • Shang Poa P Chang
  • Amber I Haugeto

Detail Information

Publications9

  1. ncbi request reprint Difluoroketones as inhibitors of matrix metalloprotease-13
    L A Reiter
    Pfizer Inc, Central Research Division, Groton, CT 06340, USA
    Bioorg Med Chem Lett 10:1581-4. 2000
    ..Weak inhibition was seen with the key target 2. This and the more potent activity of intermediate 7b illustrates that hydrated ketones can be used to inhibit MMP-13 and perhaps other members of this class of enzymes...
  2. ncbi request reprint Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3
    Lawrence A Reiter
    Pfizer Inc, Global Reseach and Development, Groton Laboratories, Eastern Point Rd, 06340, Groton, CT, USA
    Bioorg Med Chem Lett 13:2331-6. 2003
    ..Combining improved P(1)' and P(2) groups into a single molecule gave an inhibitor with a 4.5 nM IC(50) against MMP-13 and which is 270-fold selective over MMP-1...
  3. ncbi request reprint Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1
    Lawrence A Reiter
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 14:3389-95. 2004
    ..Despite the sparing of MMP-1, pre-clinical and clinical studies revealed that fibrosis in rats and MSS in humans is still produced...
  4. ncbi request reprint Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14
    Julian A Blagg
    Pfizer Global Research and Development, Groton Laboratories, MS8220 2471, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 15:1807-10. 2005
    ..Structure activity relationships of the biaryl ether substituent are presented as is pharmacokinetic data for a compound that meets our in vitro potency and selectivity goals...
  5. ncbi request reprint Potent, selective pyrimidinetrione-based inhibitors of MMP-13
    Lawrence A Reiter
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 16:5822-6. 2006
    ..In a rat fibrosis model, a compound from the series displayed no fibrosis at exposures many fold greater than its MMP-13 IC50...
  6. ncbi request reprint Pyrimidine benzamide-based thrombopoietin receptor agonists
    Lawrence A Reiter
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 17:5447-54. 2007
    ..In vivo examination revealed that compounds from the series are not highly bioavailable. This is attributed to low solubility and poor permeability...
  7. ncbi request reprint A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif
    Amit S Kalgutkar
    Pharmacokinetics, Dynamics and Metabolism Department, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Chem Res Toxicol 20:1954-65. 2007
    ..These structural changes not only abrogated the bioactivation liability associated with 1 but also resulted in compounds that retained the attractive pharmacological and pharmacokinetic attributes of the prototype agent...
  8. ncbi request reprint Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13
    Kevin D Freeman-Cook
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 17:6529-34. 2007
    ..When dosed as the sodium salt, these compounds displayed excellent oral absorption and pharmacokinetic properties. Despite the selectivity, a representative of this series produced fibroplasia in a 14 day rat study...
  9. doi request reprint Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonists
    Lawrence A Reiter
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 18:3000-6. 2008
    ..The relationship of this agonism-inducing conformation to that of other series of TPO receptor agonists is discussed...